1 Min Read
March 20 (Reuters) - Nantkwest Inc:
* Nantkwest announces FDA grant of orphan drug designation for the company’s ank natural killer cell therapy in merkel cell carcinoma Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.